Fine-tuning of NFκB by glycogen synthase kinase 3β directs the fate of glomerular podocytes upon injury

Kidney International

Volumn 87, Issue 6, 2015, Pages 1176-1190

  Bao, Hui ^a,b   Ge, Yan ^b   Peng, Ai ^a   Gong, Rujun ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

Author keywords

apoptosis; glomerulus; glycogen synthase kinase 3 ; nuclear factor B; podocyte; proteinuria

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; B7 ANTIGEN; CATHEPSIN L; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LITHIUM CHLORIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL XL; TRANSCRIPTION FACTOR RELA; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; BCL2L1 PROTEIN, MOUSE; CCL2 PROTEIN, MOUSE; CTSL PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, MOUSE; LITHIUM; PROTEIN BCL X; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; RELA PROTEIN, MOUSE; SERINE PROTEINASE INHIBITOR; THIADIAZOLE DERIVATIVE; THIOCARBAMIC ACID DERIVATIVE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL FATE; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOSKELETON; GENE EXPRESSION; GENETIC TRANSFECTION; GLOMERULUS; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PODOCYTE; PODOCYTOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CULTURE; CELL MOTION; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTIGENS, CD80; APOPTOSIS; BCL-X PROTEIN; CATHEPSIN L; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL2; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; KIDNEY GLOMERULUS; LIPOPOLYSACCHARIDES; LITHIUM; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; PHOSPHORYLATION; PODOCYTES; PROTEINURIA; PYRROLIDINES; SERINE PROTEINASE INHIBITORS; THIADIAZOLES; THIOCARBAMATES; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRANSCRIPTION FACTOR RELA;

EID: 84930271742     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.428     Document Type: Article

References (64)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease-a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169.
2. Johnson DW. Global proteinuria guidelines: are we nearly there yet? Clin Biochem Rev 2011; 32: 89-95.
3. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35: S97-105.
4. Kriz W. Evolving role of the podocyte in chronic renal failure. Kidney Blood Press Res 1997; 20: 180-183.
5. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008; 88: 451-487.
6. Shankland SJ. The podocyte?s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
7. Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009; 5: 463-468.
8. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001; 59: 415-424.
9. Brahler S, Ising C, Hagmann H et al. Intrinsic proinflammatory signaling in podocytes contributes to podocyte damage and prolonged proteinuria. Am J Physiol Renal Physiol 2012; 303: F1473-F1485.
10. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
11. Greiber S, Muller B, Daemisch P et al. Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colonystimulating factor. J Am Soc Nephrol 2002; 13: 86-95.
12. Bruggeman LA, Drawz PE, Kahoud N et al. TNFR2 interposes the proliferative and NF-kappaB-mediated inflammatory response by podocytes to TNF-alpha. Lab Invest 2011; 91: 413-425.
13. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int 2010; 77: 571-580.
14. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 1999; 18: 6896-6909.
15. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
16. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-2224.
17. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
18. Beg AA, Sha WC, Bronson RT et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995; 376: 167-170.
19. Sha WC, Liou HC, Tuomanen EI et al. Targeted Disruption of the P50 Subunit of Nf-Kappa-B Leads to Multifocal Defects in Immune-Responses. Cell 1995; 80: 321-330.
20. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009; 9: 778-788.
21. Auphan N, DiDonato JA, Rosette C et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-290.
22. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 1999; 100: 1330-1337.
23. Ha KH, Byun MS, Choi J et al. N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF-kappaB activation by blocking specific cysteine residues of IkappaB kinase beta and p65/RelA. Biochemistry 2009; 48: 7271-7278.
24. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
25. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-776.
26. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-1186.
27. Steinbrecher KA, Wilson W 3rd, Cogswell PC et al. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol 2005; 25: 8444-8455.
28. Gong R, Rifai A, Ge Y et al. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem 2008; 283: 7401-7410.
29. Reiser J, von Gersdorff G, Loos M et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397.
30. Banas MC, Banas B, Hudkins KL et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008; 19: 704-713.
31. Wang Z, Ge Y, Bao H et al. Redox-sensitive glycogen synthase kinase 3beta-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury. Free Radic Biol Med 2013; 65: 849-858.
32. Welsh GI, Saleem MA. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol 2012; 8: 14-21.
33. Chow JC, Young DW, Golenbock DT et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-10692.
34. Gong R, Ge Y, Chen S et al. Glycogen synthase kinase 3 beta: a novel marker and modulator of inflammatory injury in chronic renal allograft disease. Am J Transplant 2008; 8: 1852-1863.
35. Buss H, Dorrie A, Schmitz ML et al. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem 2004; 279: 49571-49574.
36. Srivastava T, Sharma M, Yew KH et al. LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile. J Cell Commun Signal 2013; 7: 49-60.
37. Tarabra E, Giunti S, Barutta F et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009; 58: 2109-2118.
38. Liu ZG, Hsu H, Goeddel DV et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-576.
39. Van Antwerp DJ, Martin SJ, Kafri T et al. Suppression of TNF-alphainduced apoptosis by NF-kappaB. Science 1996; 274: 787-789.
40. Tsukahara T, Kannagi M, Ohashi T et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol 1999; 73: 7981-7987.
41. Zhang J, Pippin JW, Krofft RD et al. Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol 2013; 304: F1375-F1389.
42. Messmer UK, Winkel G, Briner VA et al. Suppression of apoptosis by glucocorticoids in glomerular endothelial cells: effects on proapoptotic pathways. Br J Pharmacol 2000; 129: 1673-1683.
43. Schakman O, Kalista S, Barbe C et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013; 45: 2163-2172.
44. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005; 37: 1974-1984.
45. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426.
46. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009; 1: a000034.
47. Huang B, Yang XD, Lamb A et al. Posttranslational modifications of NFkappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal 2010; 22: 1282-1290.
48. Mattioli I, Dittrich-Breiholz O, Livingstone M et al. Comparative analysis of T-cell costimulation and CD43 activation reveals novel signaling pathways and target genes. Blood 2004; 104: 3302-3304.
49. Wang H, Kumar A, Lamont RJ et al. GSK3beta and the control of infectious bacterial diseases. Trends Microbiol 2014; 22: 208-217.
50. Hoeflich KP, Luo J, Rubie EA et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
51. Doble BW, Patel S, Wood GA et al. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 2007; 12: 957-971.
52. George B, Vollenbroker B, Saleem MA et al. GSK3beta inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility. Am J Physiol Renal Physiol 2011; 300: F1152-F1162.
53. Rai P, Plagov A, Kumar D et al. Rapamycin-induced modulation of HIV gene transcription attenuates progression of HIVAN. Exp Mol Pathol 2013; 94: 255-261.
54. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNFalpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002; 283: G204-G211.
55. Xu W, Ge Y, Liu Z et al. Glycogen synthase kinase 3beta dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy. Am J Pathol 2014; 184: 2742-2756.
56. Howard C, Tao S, Yang HC et al. Specific deletion of glycogen synthase kinase-3beta in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney Int 2012; 82: 1000-1009.
57. Bao H, Ge Y, Wang Z et al. Delayed administration of a single dose of lithium promotes recovery from AKI. J Am Soc Nephrol 2014; 25: 488-500.
58. Saleem MA, O?Hare MJ, Reiser J et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630-638.
59. Arif E, Wagner MC, Johnstone DB et al. Motor protein Myo1c is a podocyte protein that facilitates the transport of slit diaphragm protein Neph1 to the podocyte membrane. Mol Cell Biol 2011; 31: 2134-2150.
60. Wasik AA, Polianskyte-Prause Z, Dong MQ et al. Septin 7 forms a complex with CD2AP and nephrin and regulates glucose transporter trafficking. Mol Biol Cell 2012; 23: 3370-3379.
61. Ma J, Nishimura H, Fogo A et al. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998; 53: 937-944.
62. Bertelli R, Di Donato A, Cioni M et al. LPS nephropathy in mice is ameliorated by IL-2 independently of regulatory T cells activity. PLoS One 2014; 9: e111285.
63. Takemoto M, Asker N, Gerhardt H et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002; 161: 799-805.
64. Si J, Ge Y, Zhuang S et al. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int 2013; 83: 635-646.